| Histology |
OtherMesothelioma
|
| Tumor stage |
Stage III - IV |
| Host / recruiting site 1 |
Erasmus MC
|
Enrollment |
Closed
|
| Therapy line |
Later line (≥2L)
|
| Design |
- Open label, Phase I, multicenter study, 2 arms with a dose escalation part and a dose expansion part.
|
| Intervention |
- Arm A: 3 days on/ 4 days off, max 6 cycles
- Arm B: continuous dosing
|
| Key outcome parameters |
- Safety and tolerability of IAG933
|
| Key inclusion criteria |
- Advanced (unresectable or metastatic) mesothelioma, or solid tumors harboring NF2/LATS1/LATS2 truncating mutations or deletions or functional YAP/TAZ fusions
- Patient must be willing to undergo a new tumor biopsy at screening/baseline, and again during therapy on this study
- ECOG performance status 0 or 1
|
| Key exclusion criteria |
- Presence of symptomatic CNS metastases, or CNS tumors or metastases that require local CNS- directed therapy, or increasing doses of corticosteroids 2 weeks prior to study entry.
|
| Contact information |
Log in voor de contactinformatie
|
